The influence of switching from oral risperidone to risperidone long-acting injection on the clinical symptoms and cognitive function in schizophrenia

Therapeutic Advances in Psychopharmacology

Volumn 2, Issue 1, 2012, Pages 23-29

  Suzuki, Hidenobu ^a   Gen, Keishi ^a  

^a NONE

Author keywords

attention; motor processing function; risperidone long acting injection; schizophrenia

Indexed keywords

BIPERIDEN; RISPERIDONE; RISPERIDONE LONG ACTING INJECTION; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DSM-IV; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MEMORY; MENTAL CONCENTRATION; MONOTHERAPY; OBSERVATIONAL STUDY; OPEN STUDY; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; SCHIZOPHRENIA; UNSPECIFIED SIDE EFFECT; WISCONSIN CARD SORTING TEST;

EID: 84998124994     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125311430536     Document Type: Article

References (15)

1. Cuesta M.J. Peralta V. Zarzuela A. (2001) Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17-28.
2. Eerdekens M. Van Hove I. Remmerie B. Mannaert E. (2004) Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res 70: 91-100.
3. Heaton R.K. Chelune G.L. Talley J.L. Kay G.G. Curtiss G. (1993) Wisconsin Card Sorting Test Manual: revised and expanded. Odessa, FL: Psychological Assessment Resources.
4. Inagaki A. Inada T. (2010) Dose equivalence of psychotropic drugs. Part XXII: dose equivalence of depot antipsychotics III: risperidone long-acting injection. Jpn J Clin Psychopharmacol 13: 1349-1353 (in Japanese).
5. Kashima H. (2002) Tests for executive function. Jpn Psychiatry Diagnostic 13: 205-212 (in Japanese).
6. Kay S.R. Fiszbein A. Opler L.A. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
7. Kern R.S. Green M.F. Cornblatt B.A. Owen J.R. McQuade R.D. Carson W.H. et al. (2006) The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 187: 312-320.
8. Kim S.W. Shin I.S. Kim J.M. Lee Y.H. Yang S.J. Yoon J.S. (2009) Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol 24: 565-573.
9. Meltzer H.Y. McGurk S.R. (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25: 233-255.
10. Moller H.J. (2006) Long-acting risperidone: focus on safety. Clin Ther 28: 633-651.
11. Mori K. Nagano M. Yamashita H. Morinobu S. Yamawaki S. (2004) Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 28: 659-665.
12. Purdon S.E. Jones B.D.W. Stip E. Labelle D. Addington S.R. David A. et al. (2000) Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249-258.
13. Riedel M. Muller N. Spellmann I. Engel R.R. Musil R. Valdevit R. et al. (2007) Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an active episode of schizophrenia. Eur Arch Psychiatry Clin Neurosci 257: 402-412.
14. Schmauss M. Sacchetti E. Kahn J.P. Rossella M. (2007) Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone. Int Clin Psychopharmacol 22: 85-92.
15. Suzuki H. Gen K. Inoue Y. (2010) An unblended comparison of clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Progr Neuropsychopharmacol Biol Psychiatry 35: 161-168.